This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Multiple Sclerosis Association Of America Publishes 2014 MS Research Update

CHERRY HILL, N.J., Feb. 20, 2014 /PRNewswire/ -- The Multiple Sclerosis Association of America (MSAA) is pleased to offer the latest MS Research Update , available as both a printed and online publication. This vital resource provides a comprehensive overview of research findings on the ten FDA-approved disease-modifying therapies for relapsing forms of multiple sclerosis (MS), as well as the latest study results on many experimental treatments currently under investigation. Directions for future research are also presented.  

Multiple Sclerosis Association of America logo.


Included in this edition are updates on the currently approved drugs, such as the recently FDA-approved dosing option for Copaxone® and the FDA-labeling changes for Tysabri®. In addition to the exciting research aimed at relapsing forms of MS, a number of studies are now looking into the treatment of progressive forms of MS, which are highlighted in this edition of the MS Research Update for easy and quick identification. This update also features studies in areas such as stem-cell research, therapies for myelin repair and protection, biomarkers, genetic studies, and more.

Today, healthcare professionals and patients have numerous and more complex treatment options to consider. The need for patient education and awareness is crucial. This update and other MSAA resources are valuable tools for anyone looking for treatment information. Read or download the MS Research Update for free or order a printed copy at

For more information about MS and treatment options, please contact MSAA at (800) 532-7667, or visit

About MSAA

The Multiple Sclerosis Association of America (MSAA) is a national nonprofit organization and leading resource for the entire MS community, improving lives today through vital services and support. MSAA provides free programs and services, such as: a Helpline with professional consultants; award-winning publications, including MSAA's magazine, The Motivator; MSAA's nationally recognized website (at, featuring award-winning educational videos and research updates; S.E.A.R.C.H.â„¢ program to assist the MS community with learning about different treatment choices; a mobile phone app, My MS Managerâ„¢ (named one of the best multiple sclerosis iPhone & Android apps by; a resource database, My MS Resource Locator; safety and mobility equipment distribution; cooling accessories for heat-sensitive individuals; educational events held across the country; MRI funding; and more. For additional information, please visit or call (800) 532-7667.


SOURCE Multiple Sclerosis Association of America

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,839.85 +27.66 0.16%
S&P 500 2,090.63 +1.49 0.07%
NASDAQ 5,114.0660 +11.2580 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs